Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases

11/20/2020 | 08:49am EST

EAST HANOVER - Novartis announced today that new research data from a broad range of hematology medicines and investigational therapies will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, taking place virtually December 5-8.

More than 65 abstracts from Novartis-sponsored and investigator-initiated trials that include results for asciminib, Kymriah (tisagenlecleucel), Jakavi, sabatolimab (MBG453) and Adakveo (crizanlizumab) underscore the Novartis vision to deliver transformative innovation to address unmet medical needs.

'Our research and development strategy focuses on developing transformative treatments with the aspiration of dramatically improving quality of life and addressing the underlying disease process,' said Susanne Schaffert, PhD, President, Novartis Oncology. 'The ASH presentations demonstrate how we are pursuing these goals in hematology with research that focuses on developing advanced therapeutic approaches across an array of blood cancers and difficult-to-treat hematologic diseases.'

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Located in East Hanover, NJ Novartis Pharmaceuticals Corporation - an affiliate of Novartis - is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs more than 15,000 people in the United States.

Contact:

Anja von Treskow

Tel: +41 61 324 2279

Email: anja.vontreskow@novartis.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about NOVARTIS AG
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
01/15NOVARTIS AG : Gets a Buy rating from Deutsche Bank
MD
01/15NOVARTIS : Exane BNP Paribas Lowers Price Target on Novartis, Maintains Outperfo..
MT
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
MT
01/14NOVARTIS : Gets FDA Breakthrough-Therapy Designation for Ligelizumab
DJ
01/14NOVARTIS AG : UBS maintains a Buy rating
MD
01/14NOVARTIS' : Ligelizumab Receives FDA Breakthrough Therapy Designation for Urtica..
MT
01/14NOVARTIS : Skin Disease Treatment Ligelizumab Gets US FDA's Breakthrough Therapy..
MT
01/14NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language
AQ
01/14NOVARTIS : ligelizumab (QGE031) receives FDA Breakthrough Therapy designation fo..
PU
More news
Financials (USD)
Sales 2020 49 176 M - -
Net income 2020 8 396 M - -
Net Debt 2020 19 973 M - -
P/E ratio 2020 26,0x
Yield 2020 3,31%
Capitalization 218 B 218 B -
EV / Sales 2020 4,83x
EV / Sales 2021 4,42x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,22 $
Last Close Price 95,66 $
Spread / Highest target 47,2%
Spread / Average Target 14,2%
Spread / Lowest Target -14,1%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans JŲrg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG1.97%218 041
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120